UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2023-02-07 | Future report Set alerts | |
| Q3 2022 | 2022-11-03 | 0.34 | 0.34 |
| Q2 2022 | 2022-08-11 | 0.57 | 0.57 |
| Q1 2022 | 2022-05-05 | 1.07 | 1.07 |
| Q4 2021 | 2022-02-10 | 0.75 | 0.75 |
| Q3 2021 | 2021-11-04 | 1.45 | 1.45 |
| Q2 2021 | 2021-08-05 | 1.87 | 1.87 |
| Q1 2021 | 2021-04-27 | 1.89 | 1.89 |
| Q4 2020 | 2021-02-11 | 1.22 | 1.22 |
| Q3 2020 | 2020-10-29 | 1.02 | 1.02 |
| 2016-07-05 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $130.00 to $110.00 |
| 2016-06-29 | Reiterated Rating | Cantor Fitzgerald | Hold | |
| 2016-06-21 | Initiated Coverage | CL King | Buy | $165.00 |
| 2016-06-04 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-06-02 | Reiterated Rating | Cantor Fitzgerald | Hold | $165.00 |
| 2016-05-04 | Reiterated Rating | Canaccord Genuity | Hold | $160.00 to $140.00 |
| 2016-05-04 | Reiterated Rating | Stifel Nicolaus | Buy | $215.00 to $160.00 |
| 2016-05-04 | Reiterated Rating | Citigroup Inc. | Buy | $210.00 to $175.00 |
| 2016-05-04 | Reiterated Rating | Mizuho | Neutral | $150.00 to $138.00 |
| 2016-05-04 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-05-04 | Reiterated Rating | Cantor Fitzgerald | Hold | $165.00 |
| 2016-05-03 | Lower Price Target | Nomura | Buy | $210.00 to $180.00 |
| 2016-05-03 | Lower Price Target | Morgan Stanley | Equal Weight | $140.00 to $130.00 |
| 2016-05-03 | Lower Price Target | Nomura Holdings Inc. | Buy | $210.00 to $180.00 |
| 2016-04-22 | Reiterated Rating | Avondale Partners | Market Perform | $175.00 to $160.00 |
| 2016-04-22 | Reiterated Rating | Citigroup Inc. | Buy | $210.00 |
| 2016-04-19 | Reiterated Rating | BTIG Research | Hold | |
| 2016-04-19 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-04-19 | Reiterated Rating | Robert W. Baird | Hold | |
| 2016-04-19 | Reiterated Rating | Mizuho | Neutral | $150.00 |
| 2016-04-19 | Reiterated Rating | Leerink Swann | Market Perform | $175.00 to $165.00 |
| 2016-04-19 | Reiterated Rating | Cowen and Company | Outperform | $215.00 to $180.00 |
| 2016-04-19 | Downgrade | Cantor Fitzgerald | Buy to Hold | $225.00 to $165.00 |
| 2016-04-19 | Downgrade | Bank of America | Buy to Neutral | |
| 2016-04-19 | Reiterated Rating | Morgan Stanley | Equal Weight | $160.00 to $140.00 |
| 2016-04-19 | Lower Price Target | Barclays | Equal Weight | $175.00 to $160.00 |
| 2016-04-19 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2016-04-19 | Downgrade | Bank of America Corp. | Buy to Neutral | |
| 2016-04-19 | Lower Price Target | Barclays PLC | Equal Weight | $175.00 to $160.00 |
| 2016-04-18 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-04-11 | Reiterated Rating | Piper Jaffray | Buy | $204.00 |
| 2016-03-30 | Initiated Coverage | Argus | Buy | $175.00 |
| 2016-03-23 | Lower Price Target | Goldman Sachs | $141.00 | |
| 2016-03-23 | Lower Price Target | Goldman Sachs Group Inc. | $141.00 | |
| 2016-03-09 | Reiterated Rating | Canaccord Genuity | Hold | $160.00 |
| 2016-03-08 | Reiterated Rating | BTIG Research | Hold | |
| 2016-02-04 | Downgrade | Canaccord Genuity | Buy to Hold | $205.00 to $160.00 |
| 2016-02-03 | Reiterated Rating | BTIG Research | Neutral | |
| 2016-02-03 | Lower Price Target | Evercore ISI | Hold | $177.00 to $160.00 |
| 2016-02-03 | Upgrade | Piper Jaffray | Buy | $219.00 to $215.00 |
| 2016-02-03 | Reiterated Rating | Cantor Fitzgerald | Buy | $225.00 |
| 2016-02-03 | Lower Price Target | Robert W. Baird | Neutral | $180.00 to $175.00 |
| 2016-02-03 | Reiterated Rating | Deutsche Bank | Hold | $178.00 to $160.00 |
| 2016-02-03 | Reiterated Rating | Deutsche Bank AG | Hold | $178.00 to $160.00 |
| 2016-01-19 | Reiterated Rating | Piper Jaffray | Overweight | $219.00 |
| 2016-01-13 | Reiterated Rating | Mizuho | Neutral | $150.00 |
| 2016-01-13 | Reiterated Rating | BTIG Research | Neutral | |
| 2016-01-11 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-01-11 | Reiterated Rating | Canaccord Genuity | Buy | $205.00 |
| 2016-01-07 | Boost Price Target | Cowen and Company | $215.00 | |
| 2016-01-07 | Boost Price Target | Barclays | Equal Weight | $170.00 to $175.00 |
| 2016-01-07 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2016-01-07 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2016-01-06 | Initiated Coverage | Avondale Partners | Market Perform | $175.00 |
| 2016-01-06 | Initiated Coverage | Deutsche Bank | Hold | $192.00 |
| 2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $219.00 |
| 2015-12-21 | Boost Price Target | Stifel Nicolaus | Buy | $175.00 to $215.00 |
| 2015-11-24 | Lower Price Target | Goldman Sachs | Neutral | $134.00 to $133.00 |
| 2015-10-22 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-10-21 | Reiterated Rating | Mizuho | Hold | $150.00 |
| 2015-10-21 | Reiterated Rating | Piper Jaffray | Buy | $220.00 to $219.00 |
| 2015-10-21 | Boost Price Target | Wedbush | Outperform | $150.00 to $160.00 |
| 2015-10-21 | Lower Price Target | JPMorgan Chase & Co. | Overweight | $270.00 to $235.00 |
| 2015-10-21 | Lower Price Target | Janney Montgomery Scott | Neutral | $154.00 to $140.00 |
| 2015-10-21 | Lower Price Target | Goldman Sachs | Neutral | $137.00 to $134.00 |
| 2015-10-21 | Lower Price Target | Citigroup Inc. | Buy | $240.00 to $200.00 |
| 2015-10-21 | Reiterated Rating | Canaccord Genuity | Buy | $250.00 to $205.00 |
| 2015-10-13 | Lower Price Target | Barclays | Equal Weight | $215.00 to $170.00 |
| 2015-10-08 | Reiterated Rating | William Blair | Buy | |
| 2015-10-07 | Reiterated Rating | Leerink Swann | Hold | |
| 2015-10-06 | Lower Price Target | Goldman Sachs | Neutral | $230.00 to $137.00 |
| 2015-10-06 | Lower Price Target | Leerink Swann | Market Perform | $185.00 to $155.00 |
| 2015-10-06 | Lower Price Target | Piper Jaffray | Overweight | $230.00 to $220.00 |
| 2015-10-06 | Reiterated Rating | Canaccord Genuity | Buy | $250.00 |
| 2015-10-06 | Lower Price Target | Stifel Nicolaus | Buy | $235.00 to $175.00 |
| 2015-10-06 | Downgrade | BTIG Research | Buy to Neutral | |
| 2015-10-06 | Downgrade | Mizuho | Buy to Neutral | $250.00 to $150.00 |
| 2015-10-06 | Reiterated Rating | Evercore ISI | Hold | |
| 2015-10-06 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2015-10-02 | Reiterated Rating | Cowen and Company | Outperform | $300.00 to $220.00 |
| 2015-10-01 | Downgrade | Leerink Swann | Outperform to Market Perform | $225.00 to $185.00 |
| 2015-09-30 | Reiterated Rating | Stifel Nicolaus | Buy | $235.00 to $175.00 |
| 2015-09-16 | Reiterated Rating | BTIG Research | Buy | $240.00 |
| 2015-08-26 | Initiated Coverage | Cantor Fitzgerald | Buy | $265.00 |
| 2015-08-26 | Upgrade | Citigroup Inc. | Focus List | |
| 2015-08-22 | Reiterated Rating | Canaccord Genuity | Buy | $250.00 |
| 2015-08-19 | Reiterated Rating | BTIG Research | Buy | $240.00 |
| 2015-08-19 | Reiterated Rating | Mizuho | Buy | $240.00 to $250.00 |
| 2015-07-23 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-07-22 | Reiterated Rating | Piper Jaffray | Buy | $230.00 |
| 2015-07-22 | Lower Price Target | Canaccord Genuity | Buy | $275.00 to $250.00 |
| 2015-07-22 | Downgrade | Janney Montgomery Scott | Buy to Neutral | $240.00 |
| 2015-07-22 | Boost Price Target | Mizuho | Buy | $230.00 to $240.00 |
| 2015-07-17 | Reiterated Rating | BTIG Research | Buy | |
| 2015-07-17 | Initiated Coverage | Canaccord Genuity | Buy | $275.00 |
| 2015-07-16 | Reiterated Rating | Piper Jaffray | Overweight | $230.00 |
| 2015-07-14 | Reiterated Rating | Wedbush | Buy | $230.00 to $250.00 |
| 2015-07-01 | Boost Price Target | Cowen and Company | Outperform | $264.00 to $300.00 |
| 2015-06-03 | Reiterated Rating | Leerink Swann | Positive | $225.00 |
| 2015-05-26 | Reiterated Rating | BTIG Research | Buy | $240.00 |
| 2015-05-21 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $190.00 to $162.00 |
| 2015-04-26 | Reiterated Rating | Cantor Fitzgerald | Hold | $169.00 |
| 2015-04-26 | Reiterated Rating | BTIG Research | Buy | $240.00 |
| 2015-04-23 | Upgrade | Tigress Financial | Buy to Strong-Buy | $421.00 to $539.00 |
| 2015-04-22 | Reiterated Rating | Citigroup Inc. | Buy | $215.00 to $240.00 |
| 2015-04-22 | Set Price Target | Mizuho | Buy | $220.00 to $230.00 |
| 2015-03-31 | Set Price Target | BTIG Research | Buy | $240.00 |
| 2015-02-03 | Reiterated Rating | Cantor Fitzgerald | Hold | $166.00 |
| 2015-01-28 | Boost Price Target | Barclays | Equal Weight | $210.00 to $215.00 |
| 2015-01-28 | Set Price Target | Credit Suisse | Buy | $230.00 |
| 2015-01-28 | Boost Price Target | Stifel Nicolaus | Buy | $215.00 to $235.00 |
| 2015-01-28 | Reiterated Rating | Janney Montgomery Scott | Buy | $192.00 to $221.00 |
| 2015-01-28 | Set Price Target | Wedbush | Buy | $200.00 to $230.00 |
| 2015-01-28 | Boost Price Target | Maxim Group | Buy | $236.00 to $255.00 |
| 2015-01-28 | Reiterated Rating | BTIG Research | Buy | $240.00 |
| 2015-01-28 | Set Price Target | Credit Suisse Group AG | Buy | $230.00 |
| 2015-01-07 | Initiated Coverage | Barclays | Equal Weight to Equal Weight | $210.00 |
| 2015-01-06 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $230.00 to $270.00 |
| 2014-10-27 | Boost Price Target | Stifel Nicolaus | Buy | $200.00 to $215.00 |
| 2014-10-21 | Reiterated | ISI Group | Neutral | $175 to $180.50 |
| 2014-10-21 | Boost Price Target | Bank of America | $220.00 | |
| 2014-10-21 | Upgrade | Janney Montgomery Scott | Neutral to Buy | $165.00 to $192.00 |
| 2014-10-21 | Boost Price Target | Evercore ISI | Neutral | $175.00 to $180.50 |
| 2014-10-21 | Boost Price Target | Piper Jaffray | $210.00 | |
| 2014-10-16 | Upgrade | Piper Jaffray | Neutral to Overweight | $166.00 to $192.00 |
| 2014-10-03 | Initiated Coverage | ING Group | Buy | $220.00 |
| 2014-10-02 | Initiated Coverage | BTIG Research | Buy | |
| 2014-09-08 | Initiated Coverage | Morgan Stanley | Equal Weight | $190.00 |
| 2014-08-20 | Upgrade | Wedbush | Neutral to Outperform | $165.00 to $200.00 |
| 2014-08-11 | Initiated Coverage | Stifel Nicolaus | Buy | $200.00 |
| 2014-08-05 | Boost Price Target | Goldman Sachs | $184.00 to $187.00 | |
| 2014-08-01 | Initiated Coverage | Tigress Financial | Buy | |
| 2014-07-24 | Reiterated Rating | Credit Suisse | Outperform | $180.00 to $198.00 |
| 2014-07-24 | Reiterated Rating | JPMorgan Chase & Co. | Overweight | $190.00 to $230.00 |
| 2014-07-24 | Reiterated Rating | Macquarie | Outperform | $177.00 to $200.00 |
| 2014-07-24 | Boost Price Target | Mizuho | Buy | $200.00 to $220.00 |
| 2014-07-24 | Boost Price Target | Leerink Swann | Outperform | $180.00 to $195.00 |
| 2014-07-17 | Boost Price Target | Maxim Group | Buy | $205.00 to $220.00 |
| 2014-07-17 | Initiated Coverage | Citigroup Inc. | Buy | $215.00 |
| 2014-04-28 | Upgrade | Ned Davis Research | Sell to Neutral | |
| 2014-04-23 | Reiterated | ISI Group | Neutral | $152.50 to $162.50 |
| 2014-04-23 | Upgrade | Maxim Group | Hold to Buy | $205.00 |
| 2014-04-23 | Reiterated Rating | Bank of America | Buy | $195.00 |
| 2014-04-23 | Boost Price Target | Leerink Swann | Outperform | $160.00 to $180.00 |
| 2014-04-23 | Boost Price Target | Mizuho | Buy | $175.00 to $200.00 |
| 2014-04-23 | Boost Price Target | Evercore ISI | Neutral | $152.50 to $162.50 |
| 2014-04-11 | Lower Price Target | Goldman Sachs | Neutral | $162.00 to $160.00 |
| 2014-04-07 | Reiterated Rating | Wells Fargo & Co. | Top Pick | |
| 2014-04-07 | Reiterated Rating | Wells Fargo | Top Pick | |
| 2014-04-02 | Upgrade | Macquarie | Neutral to Outperform | $125.00 to $170.00 |
| 2014-03-10 | Boost Price Target | Cowen and Company | $190.00 to $195.00 | |
| 2014-03-05 | Boost Price Target | JMP Securities | $167.00 to $215.00 | |
| 2014-02-18 | Boost Price Target | Bank of America | $165.00 to $190.00 | |
| 2014-01-29 | Reiterated | ISI Group | Neutral | $134.50 to $147 |
| 2014-01-29 | Set Price Target | Leerink Swann | $140.00 to $160.00 | |
| 2014-01-29 | Boost Price Target | Mizuho | Buy | $150.00 to $175.00 |
| 2014-01-29 | Boost Price Target | Evercore ISI | Neutral | $134.50 to $147.00 |
| 2014-01-17 | Boost Price Target | Leerink Swann | $110.00 to $140.00 | |
| 2014-01-17 | Boost Price Target | Robert W. Baird | $87.00 to $137.00 | |
| 2014-01-17 | Boost Price Target | JPMorgan Chase & Co. | $120.00 to $190.00 | |
| 2014-01-17 | Boost Price Target | Bank of America | Buy | $20.00 to $165.00 |
| 2014-01-14 | Reiterated Rating | Mizuho | Buy | $125.00 to $135.00 |
| 2013-12-20 | Boost Price Target | Cowen and Company | $125.00 | |
| 2013-12-19 | Boost Price Target | Mizuho | Buy | $100.00 to $125.00 |
| 2013-12-18 | Initiated Coverage | JMP Securities | Market Perform to Outperform | $125.00 |
| 2013-10-23 | Boost Price Target | Wedbush | Neutral | $65.00 to $72.00 |
| 2013-10-23 | Boost Price Target | Janney Montgomery Scott | Neutral | $86.00 to $89.00 |
| 2013-10-23 | Boost Price Target | Cantor Fitzgerald | Hold | $63.00 to $72.00 |
| 2013-10-22 | Boost Price Target | Evercore ISI | Neutral | $85.00 |
| 2013-10-22 | Boost Price Target | Barclays | Overweight | $85.00 to $90.00 |
| 2013-10-22 | Boost Price Target | Credit Suisse | Outperform | $84.00 to $95.00 |
| 2013-10-22 | Boost Price Target | Mizuho | Buy | $86.00 to $100.00 |
| 2013-10-15 | Boost Price Target | Wedbush | Neutral | $60.00 to $65.00 |
| 2013-09-27 | Reiterated Rating | Bank of America | Buy | $90.00 |
| 2013-09-27 | Boost Price Target | Goldman Sachs | Neutral | $73.00 to $74.00 |
| 2013-07-24 | Reiterated | ISI Group | Neutral | $75 to $78.50 |
| 2013-04-09 | Reiterated | Mizuho | Buy | $57 to $61 |
| 2013-01-29 | Reiterated | Cantor Fitzgerald | Hold | $45 to $48 |
| 2016-07-05 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $130.00 to $110.00 |
| 2016-06-29 | Reiterated Rating | Cantor Fitzgerald | Hold | |
| 2016-06-21 | Initiated Coverage | CL King | Buy | $165.00 |
| 2016-06-04 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-06-02 | Reiterated Rating | Cantor Fitzgerald | Hold | $165.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ILMN 598 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BAILLIE GIFFORD & CO | 19.02M |
| Vanguard Group, Inc | 12.84M |
| BlackRock Inc. | 11.78M |
| EDGEWOOD MANAGEMENT LLC | 7.43M |
| STATE STREET CORP | 6.57M |
| BlackRock Fund Advisors | 4.70M |
| POLEN CAPITAL MANAGEMENT LLC | 4.52M |
| BlackRock Institutional Trust Company, N.A. | 3.86M |
| LOOMIS SAYLES & CO L P | 3.60M |
| WELLINGTON MANAGEMENT CO LLP | 3.35M |
| MORGAN STANLEY | 3.18M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.81M |
| CITADEL ADVISORS LLC | 2.08M |
| Invesco Ltd. | 1.92M |
| HENDERSON GROUP PLC | 1.77M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| WALT DAVID R | 454561.15% (631840) | CERU / ILMN / |
| FLATLEY JAY T CEO | 288362.59% (400824) | COHR / ILMN / |
| ORPIN TRISTAN EVP Clinical Genomics | 85579.86% (118956) | ILMN / |
| deSouza Francis A President | 63720.14% (88571) | CTXS / DIS / ILMN / SYMC / |
| Ronaghi Mostafa Sr VP & CTO | 51076.26% (70996) | ILMN / |
| Bianchi Paul L Sr VP, Human Resources | 47237.41% (65660) | ILMN / |
| Naclerio Nicholas Sr VP, Corporate & Venture Dev | 21597.12% (30020) | ILMN / |
| OSTADAN OMEAD Sr VP Product Dev & Operations | 19534.53% (27153) | ILMN / |
| Klausner Richard Sr VP, Chief Medical Officer | 16436.69% (22847) | ILMN / |
| MOELLER GERALD | 12695.68% (17647) | ILMN / |
| HENRY CHRISTIAN O SVP, Chief Commercial Officer | 12612.23% (17531) | ILMN / |
| BOWMAN A BLAINE | 12135.25% (16868) | ILMN / |
| BRADBURY DANIEL | 11024.46% (15324) | BMR / CORT / GERN / ICPT / ILMN / |
| Stapley Marc Sr VP & CFO | 9918.71% (13787) | ILMN / |
| EASTHAM KARIN | 9559.71% (13288) | GERN / ILMN / VCYT / |
| Van Oene Mark SVP Chief Commercial Officer | 8789.21% (12217) | ILMN / |
| ARNOLD FRANCES | 7330.22% (10189) | ILMN / |
| Bouchard Michel Chief Accounting Officer | 6861.87% (9538) | ILMN / |
| RASTETTER WILLIAM H | 6110.79% (8494) | CERU / FATE / ILMN / NBIX / RCPT / RGLS / |
| Dadswell Charles Sr VP & General Counsel | 5665.47% (7875) | ILMN / |
| DORSA CAROLINE | 5252.52% (7301) | BIIB / ILMN / NTLA / PEG / |
| SCHILLER PHILIP W | 5205.76% (7236) | AAPL / ILMN / |
| EPSTEIN ROBERT S | 5099.28% (7088) | AVEO / FATE / ILMN / VCYT / |
| Hampton Malcolm Garret EVP Clinical Genomics Group | 4642.45% (6453) | ILMN / |
| Huber Jeff | 4358.99% (6059) | EA / ILMN / |
| THOMPSON JOHN WENDELL | 3104.32% (4315) | ILMN / MSFT / |
| GUTHART GARY S | 2555.40% (3552) | AFFX / ILMN / ISRG / |
| SAMAD SAMER ABDUL Sr. VP and CFO | 2468.35% (3431) | ILMN / |
| WHITFIELD ROY A | 2052.52% (2853) | ILMN / INCY / NKTR / |
| Hoyt Aimee L SVP, Chief People Officer | 1109.35% (1542) | ILMN / |
| MCGINNIS KAREN K VP, Chief Accounting Officer | 960.43% (1335) | ILMN / MCZ / |
UM